Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) EBT (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed EBT for 10 consecutive years, with $12.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 162.19% year-over-year to $12.7 million, compared with a TTM value of $86.7 million through Dec 2025, up 196.16%, and an annual FY2025 reading of $86.7 million, up 196.16% over the prior year.
  • EBT was $12.7 million for Q4 2025 at Zevra Therapeutics, up from -$977000.0 in the prior quarter.
  • Across five years, EBT topped out at $76.9 million in Q2 2025 and bottomed at -$33.2 million in Q3 2024.
  • Average EBT over 5 years is -$4.4 million, with a median of -$4.7 million recorded in 2021.
  • The sharpest move saw EBT surged 622.12% in 2021, then tumbled 650.09% in 2024.
  • Year by year, EBT stood at -$2.7 million in 2021, then surged by 342.38% to $6.5 million in 2022, then plummeted by 407.5% to -$19.9 million in 2023, then decreased by 2.39% to -$20.4 million in 2024, then surged by 162.19% to $12.7 million in 2025.
  • Business Quant data shows EBT for ZVRA at $12.7 million in Q4 2025, -$977000.0 in Q3 2025, and $76.9 million in Q2 2025.